Deficiency of anterior pituitary hormones in Noonan syndrome and its impact on response to growth hormone therapy

Table 2 Comparison between Noonan syndrome with and without combined pituitary hormone deficiency

Parameter	NS with CPHD (n = 5)	NS without CPHD (n = 6)	P value
Age	12.0 (11.0, 14.0)	8.8 (7.4, 10.1)	0.360
Height (cm)	117.5 (89.0, 126.0)	114.0 (106.5, 122.3)	0.790
Ht-SDS	-4.18 (-4.36, -4.17)	-2.52 (-2.76, -2.27)	0.009
Noonan specific Ht-SDS	-1.99 (-2.30, -1.59)	-0.61 (-0.74, 0.40)	0.020
Bodyweight (kg)	18 (10, 19)	19 (15, 27)	0.430
Bodyweight SDS	-5.05 (-6.32, -3.63)	-2.22 (-2.81, -1.99)	0.050
BMI (kg/m2)	13.37 (11.34, 13.77)	14.66 (13.21, 15.23)	0.330
BMI-SDS	-3.54 (-3.96, -3.49)	-1.00 (-1.59, -0.50)	0.009
IGF-1 (ng/mL)	149 (86, 179)	175 (154, 206)	0.330
IGF-1 SDS	-1.59 (-1.94, -1.10)	0.22 (-1.00, 1.17)	0.070
Height velocity in first year with GH	9.2 (8.4, 9.6)	5.5 (4.3, 6.0)	0.067
Ht-SDS (%) increment in 1 year	11.70 (5.09, 17.49)	3.32 (-3.82, 13.90)	0.430
Low IGF-1 (< -2 SDS)	2 (40)	2 (33)	0.990
GH deficiency seen on stimulation tests	4 (80)	1 (17)	0.080
IGF-1 SDS (%) increment in 1 year	78.45 (48.35, 89.26)	64.76 (59.53, 69.98)	0.860
Genetic test ( n = 5)	PTPN11 mutation: 3; POU1F1: 1	PTPN11 mutation: 2	> 0.990
Cardiac defects	4 (80); Pulmonary stenosis: 3; ASD: 2	3 (50); Pulmonary regurgitation: 1; ASD: 1; ASH: 1	0.550
Chest deformity	4 (80)	5 (83)	> 0.990
Family history	0	1
Cryptorchidism	50% of males	60% of males	> 0.990
Mental retardation	1 (20)	1 (17)	> 0.990
Coagulation defects	0	1 (17)
Lymphatic dysplasia	1 (20)	2 (33)	> 0.990
Neuropsychological impairments, language delay	1 (20)	2 (33)	> 0.990

Data are expressed as median (interquartile range) and expressed as (25^th percentile, 75^th percentile) or as n (%). NS: Noonan syndrome; CPHD: Combined pituitary hormone deficiency; SDS: Standard deviation score; BMI: Body mass index; IGF-1: Insulin like growth factor 1; GH: Growth hormone; ASD: Atrial septal defect; ASH: Asymmetric septal hypertrophy; Ht: Height.